In the triple-negative breast cancer MDA-MB-231 cell line, sulforaphane enhances the intracellular accumulation and anticancer action of doxorubicin encapsulated in liposomes.


Journal

International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127

Informations de publication

Date de publication:
10 Mar 2019
Historique:
received: 14 08 2018
revised: 03 12 2018
accepted: 02 01 2019
pubmed: 15 1 2019
medline: 14 6 2019
entrez: 15 1 2019
Statut: ppublish

Résumé

A new combination of sulforaphane (a natural compound obtained from Brassicaceae vegetables) and the cytostatic drug doxorubicin was entrapped in nanometer-sized liposomes. In vitro experiments were performed to investigate the cytotoxicity of these structures on the human breast cancer cell line MDA-MB-231. Confocal microscopy studies revealed enhanced cellular endocytotic internalization, followed by the release of the examined combination from the lysosomes. The in vitro interaction analysis using the Chou-Talalay approach showed high synergistic activity of the examined combination. This synergistic activity enables a considerable reduction in cytostatic dosage and an increase in cancer treatment efficiency.

Identifiants

pubmed: 30641176
pii: S0378-5173(19)30034-1
doi: 10.1016/j.ijpharm.2019.01.008
pii:
doi:

Substances chimiques

Antibiotics, Antineoplastic 0
Anticarcinogenic Agents 0
Isothiocyanates 0
Liposomes 0
Sulfoxides 0
Doxorubicin 80168379AG
sulforaphane GA49J4310U

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

311-318

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Lidia Mielczarek (L)

Department of Drug Biotechnology and Bioinformatics, National Medicines Institute, Chełmska 30/34, 00-725 Warsaw, Poland; Department of Drug Analysis, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, Poland.

Pamela Krug (P)

Department of Drug Biotechnology and Bioinformatics, National Medicines Institute, Chełmska 30/34, 00-725 Warsaw, Poland; Department of Chemistry, University of Warsaw, Pasteura 1, 02-093 Warsaw, Poland.

Maciej Mazur (M)

Department of Chemistry, University of Warsaw, Pasteura 1, 02-093 Warsaw, Poland.

Małgorzata Milczarek (M)

Department of Drug Biotechnology and Bioinformatics, National Medicines Institute, Chełmska 30/34, 00-725 Warsaw, Poland.

Zdzisław Chilmonczyk (Z)

Department of Drug Biotechnology and Bioinformatics, National Medicines Institute, Chełmska 30/34, 00-725 Warsaw, Poland.

Katarzyna Wiktorska (K)

Department of Drug Biotechnology and Bioinformatics, National Medicines Institute, Chełmska 30/34, 00-725 Warsaw, Poland. Electronic address: k.wiktorska@nil.gov.pl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH